Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Global patterns and trends in the incidence of non-Hodgkin lymphoma

(2019) Adalberto Miranda-Filho et al.   CANCER CAUSES & CONTROL

Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia

(2019) Ian W. Flinn et al.   AMERICAN JOURNAL OF HEMATOLOGY

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

(2019) Franck Morschhauser et al.   MOLECULAR CANCER THERAPEUTICS

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

(2019) Martin Dreyling et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Idelalisib-associated Colitis

(2015) Anna-Sophie Weidner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

(2015) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy – Lymphoma Symptom Index

(2013) Fay J. Hlubocky et al.   LEUKEMIA & LYMPHOMA

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

(2011) Bertrand Coiffier et al.   LANCET ONCOLOGY

Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies

(2011) Jonathan H. Schatz   Current Oncology Reports

Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results

(2010) Kensei Tobinai et al.   CANCER SCIENCE